• Issue

    The Prostate: Volume 82, Issue 16

    1481-1571
    December 1, 2022
Previous Issue|Next Issue
Export Citation(s)Download PDF(s)

ISSUE INFORMATION

Free Access

Issue Information

  • Page: 1481
  • First Published: 30 October 2022

ORIGINAL ARTICLES

Radiographic paradoxical response in metastatic castrate-resistant prostate cancer (mCRPC) managed with new generation anti-androgens: a retrospective analysis

Jamal Alamiri MB, BCh, BAO,  Cameron J. Britton MD,  Mohamed E. Ahmed MB, BCh,  Jack R. Andrews MD,  Julianna L. Higa BS,  Ayca Dundar MD,  R. Jeffrey Karnes MD,  Eugene Kwon MD,  Val J. Lowe MD,  Ayse T. Kendi MD,  Michael S. Bold MD,  Lance C. Pagliaro MD, 
  • Pages: 1483-1490
  • First Published: 11 September 2022

Differential effects of omega-3 PUFAS on tumor progression at early and advanced stages in TRAMP mice

Gustavo M. Amaro MS,  Alana D. T. da Silva MS,  Guilherme H. Tamarindo PhD,  Celina de A. Lamas PhD,  Sebastião R. Taboga PhD,  Valéria Helena Alves Cagnon PhD,  Rejane M. Góes PhD, 
  • Pages: 1491-1504
  • First Published: 29 August 2022

Localization of macrophage subtypes and neutrophils in the prostate tumor microenvironment and their association with prostate cancer racial disparities

Janielle P. Maynard PhD,  Taylor N. Godwin,  Jiayun Lu PhD,  Igor Vidal MD,  Tamara L. Lotan MD,  Angelo M. De Marzo MD, PhD,  Corinne E. Joshu PhD,  Karen S. Sfanos PhD, 
  • Pages: 1505-1519
  • First Published: 16 August 2022

Prostate cancer grade downgrading at time of prostatectomy provides risk-stratification insight into future tumor behavior after prostatectomy

Shu Wang MD,  J. Ryan Russell MD, MS,  Max Drescher MD,  Ashley Park MD,  Teklu Legesse MD,  Vikas Kundra MD, PhD,  Phuoc T. Tran MD, PhD,  Michael Phelan MD,  Michael Naslund MD,  M. Minhaj Siddiqui MD, 
  • Pages: 1520-1528
  • First Published: 03 August 2022

PSA provocation by bipolar androgen therapy may predict duration of response to first-line androgen deprivation: Updated results from the BATMAN study

Samuel Denmeade MD,  Su J. Lim MS,  Pedro Isaaccson Velho MD,  Hao Wang PhD, 
  • Pages: 1529-1536
  • First Published: 08 August 2022

Circulating microRNA profiling for prediction of oncological outcomes in prostate cancer patients following radical prostatectomy

Hajime Takamori MD,  Fumihiko Urabe MD, PhD,  Juntaro Matsuzaki MD, PhD,  Shoji Kimura MD, PhD,  Hiroshi Sasaki MD, PhD,  Takahiro Kimura MD, PhD,  Koji Inaba MD, PhD,  Eijiro Nakamura MD, PhD,  Yoshiyuki Matsui MD, PhD,  Hiroyuki Fujimoto MD, PhD,  Takahiro Ochiya PhD, 
  • Pages: 1537-1546
  • First Published: 16 August 2022
Open Access

Prostate cancer cells demonstrate unique metabolism and substrate adaptability acutely after androgen deprivation therapy

Mikolaj J. Filon MD,  Amani A. Gillette PhD,  Bing Yang PhD,  Tariq A. Khemees MD,  Melissa C. Skala PhD,  David F. Jarrard MD, 
  • Pages: 1547-1557
  • First Published: 18 August 2022

Are higher pre-diagnosis follicle stimulating hormone levels associated with long-term prostate cancer risk?

Kyle Dymanus MD,  Lauren E. Howard MS,  Taofik Oyekunle MS,  Amanda M. De Hoedt MS,  Artak Labadzhyan MD,  Thomas Polascik MD,  Stephen J. Freedland MD,  Zachary Klaassen MD, MSc, 
  • Pages: 1558-1563
  • First Published: 18 August 2022

CD47 (don't eat me signal) expression levels and its relationship with clinicopathologic features in early-stage prostate carcinoma

Hüseyin S. Semiz MD,  Ülkü Küçük MD,  Erdem Kısa MD,  Merve Keskinkılıç MD,  Dilara Ecem Süyün MD,  Mehmet Emin Arayıcı RD, MPH, PhD(c),  Elif Atağ MD,  Aziz Karaoglu MD, 
  • Pages: 1564-1571
  • First Published: 28 August 2022